{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:39:20Z","timestamp":1790487560170,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.beha.2017.10.001","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T20:31:50Z","timestamp":1507667510000},"page":"301-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["How can one optimize induction therapy in AML?"],"prefix":"10.1016","volume":"30","author":[{"given":"Selina M.","family":"Luger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.beha.2017.10.001_bib1","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V13.12.1126.1126","article-title":"A\u00a0comparative study of two regimens of combination chemotherapy in acute leukemia","volume":"13","author":"Frei","year":"1958","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2017.10.001_bib2","first-page":"2023","article-title":"A\u00a0randomized clinical trial of daunorubicin and a combination of prednisone, vincristine, 6-mercaptopurine, and methotrexate in adult acute nonlymphocytic leukemia","volume":"32","author":"Wiernik","year":"1972","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.beha.2017.10.001_bib3","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother Rep"},{"issue":"6","key":"10.1016\/j.beha.2017.10.001_bib4","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood.V58.6.1203.1203","article-title":"Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B","volume":"58","author":"Rai","year":"1981","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2017.10.001_bib5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V60.2.454.454","article-title":"Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study","volume":"60","author":"Yates","year":"1982","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2017.10.001_bib6","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"Lowenberg","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2017.10.001_bib7","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.2009.23.2652","article-title":"Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study","volume":"28","author":"Pautas","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2017.10.001_bib8","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","article-title":"Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study","volume":"117","author":"Ohtake","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2017.10.001_bib9","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841","article-title":"A\u00a0randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study","volume":"88","author":"Weick","year":"1996","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2017.10.001_bib10","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V87.5.1710.1710","article-title":"A\u00a0randomized study of high-dose cytarabine in induction in acute myeloid leukemia","volume":"87","author":"Bishop","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2017.10.001_bib11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2013.51.8571","article-title":"High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial","volume":"32","author":"Willemze","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.beha.2017.10.001_bib12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.beha.2017.10.001_bib13","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-07-657403","article-title":"Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups","volume":"127","author":"Luskin","year":"2016","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.beha.2017.10.001_bib14","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A\u00a0randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2017.10.001_bib15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2016-04-712091","article-title":"Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia","volume":"128","author":"Burnett","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2017.10.001_bib16","article-title":"SWOG S1203: a randomized phase III study of standard cytarabine plus daunorubicin (7+3) therapy versus idarubicin with high dose cytarabine (IA) with or without vorinostat (IA+V) in younger patients with previously untreated acute myeloid leukemia (AML)","volume":"128","author":"Garcia-Manero","year":"2016","journal-title":"Blood (ASH Annual Meeting)"},{"issue":"9","key":"10.1016\/j.beha.2017.10.001_bib17","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood-2009-07-229492","article-title":"P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: cancer and Leukemia Group B study 19808","volume":"116","author":"Kolitz","year":"2010","journal-title":"Blood"},{"issue":"9825","key":"10.1016\/j.beha.2017.10.001_bib18","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.beha.2017.10.001_bib19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.beha.2017.10.001_bib20","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2017.10.001_bib21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.leu.2403336","article-title":"Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study","volume":"18","author":"Holowiecki","year":"2004","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2017.10.001_bib22","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1182\/blood-2016-10-740613","article-title":"Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML","volume":"129","author":"Lowenberg","year":"2017","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2017.10.001_bib23","article-title":"Vadastuximab talirine monotherapy in older patients with treatment naive CD33-positive acute myeloid leukemia (AML)","volume":"128","author":"Bixby","year":"2016","journal-title":"Blood (ASH Annual Meeting)"},{"issue":"22","key":"10.1016\/j.beha.2017.10.001_bib24","article-title":"A\u00a0phase 1b study of vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed acute myeloid leukemia (AML)","volume":"128","author":"Erba","year":"2016","journal-title":"Blood (ASH Annual Meeting)"},{"issue":"23","key":"10.1016\/j.beha.2017.10.001_bib25","volume":"126","author":"Foran","year":"2015","journal-title":"Blood (ASH Annual Meeting)"},{"issue":"4","key":"10.1016\/j.beha.2017.10.001_bib26","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2017.10.001_bib27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2017.10.001_bib28","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.10.001_bib29","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ajh.24016","article-title":"Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients >\/=60 years old","volume":"90","author":"Gupta","year":"2015","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1016\/j.beha.2017.10.001_bib30","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2017.10.001_bib31","article-title":"Survival following allogeneic hematopoietic cell transplantation in older high-risk acute myeloid leukemia patients initially treated with CPX-351 liposome injection versus standard cytarabine and daunorubicin: subgroup analysis of a large phase III trial","volume":"128","author":"Lancet","year":"2016","journal-title":"Blood (ASH Annual Meeting)"},{"issue":"22","key":"10.1016\/j.beha.2017.10.001_bib32","article-title":"Analysis of efficacy by age for patients aged 60-75 with untreated secondary acute myeloid leukemia (AML) treated with CPX-351 liposome injection versus conventional cytarabine and daunorubicin in a phase III trial","volume":"128","author":"Medeiros","year":"2016","journal-title":"Blood (ASH Annual Meeting)"},{"issue":"15_suppl","key":"10.1016\/j.beha.2017.10.001_bib33","article-title":"Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML","volume":"34","author":"Lancet","year":"2016","journal-title":"J\u00a0Clin Oncol (ASCO Annual Meeting)"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T08:22:20Z","timestamp":1603095740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692617300518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1521692617300518"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2017.10.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How can one optimize induction therapy in AML?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2017.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}